在连续的尼甘治疗期间,尽管有血液动力学耐受性,但血小板的持续抑制
1Department of Medicine, Montreal Heart Institute, University of Montreal Medical School, Canada.
Circulation
|March 4, 1997
概括
连续的酸甘治疗始终降低了血小板沉积和聚合,即使血液动力学耐受性发展. 这表明持续的抗血小板作用对心血管健康至关重要.
科学领域:
- 心血管药理学心血管药理学
- 血液动力学 血液动力学
- 血小板生物学 血小板生物学
背景情况:
- 在动物和人类研究中,酸甘油表现出抗血小板性质.
- 众所周知,耐受性酸甘的血液动力学效应发生在连续治疗.
- 在连续治疗期间,酸甘的抗血小板作用的持续性仍然不清楚.
研究的目的:
- 为了研究是否耐受性发展到持续的酸甘治疗的抗血小板作用.
- 评估持续的尼特洛甘油给药对血小板功能和沉积的影响.
主要方法:
- 猪大动脉介质暴露于来自对照猪和接受连续酸甘贴片 (0.8 mg/h) 的猪的动脉血液.
- 在高剪切条件下,使用自主51Cr标记的血小板测量了大动脉介质上的血小板沉积.
- 评估了由血栓激素诱导的血小板聚合和血小板内循环诺辛单酸盐 (cGMP) 水平.
主要成果:
- 与基线相比,在3,24和48小时内,连续的酸甘治疗显著减少了对大动脉介质的血小板沉积.
- 在整个48小时的治疗期间,血小板聚合因氨酸引起的显著下降.
- 酸甘油的使用导致血小板内cGMP水平增加,表明持续的药理作用.
结论:
- 连续的酸甘治疗保持其抗血小板功效,尽管对其血液动力学效应的耐受性发展.
- 这项研究表明,在持续使用酸甘时,持续抑制血小板功能和沉积在受伤的动脉壁上.
- 这些发现凸显了酸甘抗血小板作用在治疗心血管疾病方面的重要性.
相关概念视频
01:28Nitric Oxide Signaling Pathway
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
01:23Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:16Antianginal Drugs: Nitrates and β-Blockers
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:27Angina II: Classification
Angina, also known as angina pectoris, is a chest pain resulting from diminished blood flow to the heart muscle and is often a symptom of coronary artery disease. Angina presents several variants with distinctive attributes, etiologies, and therapeutic approaches. The main types of angina include stable, unstable, variant (Prinzmetal's), microvascular, intractable, and silent ischemia.Stable angina is caused by atherosclerosis, which leads to the formation of plaques that narrow the coronary...